Search

Your search keyword '"van Dijk BAC"' showing total 53 results

Search Constraints

Start Over You searched for: Author "van Dijk BAC" Remove constraint Author: "van Dijk BAC"
53 results on '"van Dijk BAC"'

Search Results

1. Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands

2. Feedback preferences of patients, professionals and health insurers in integrated head and neck cancer care

Catalog

Books, media, physical & digital resources

4. Progress against laryngeal cancer in The Netherlands between 1989 and 2010

5. Sinonasal Squamous Cell Carcinoma in the Netherlands: A Population-Based Study of 568 Cases Diagnosed in 2008-2021.

6. Sinonasal mucosal melanoma in The Netherlands between 2001 and 2021: a clinical and epidemiological overview of 320 cases.

7. Evaluation of a new two-step frailty assessment of head and neck patients in a prospective cohort.

8. Chronic Stress Related to Cancer Incidence, including the Role of Metabolic Syndrome Components.

9. [Untitled]

10. Differences in the association of time to treatment initiation and survival according to various head and neck cancer sites in a nationwide cohort.

11. Nasopharyngeal carcinoma: nationwide trends in subtype-specific incidence and survival over 3 decades in a non-endemic area.

12. The relation between hypoxia and proliferation biomarkers with radiosensitivity in locally advanced laryngeal cancer.

13. Association of Tumor Microenvironment with Biological and Chronological Age in Head and Neck Cancer.

14. A nationwide study on cancer recurrences, second primary tumours, distant metastases and survival after treatment for primary head and neck cancer in the Netherlands.

15. Is locally advanced head and neck cancer 'increasing' in the Netherlands? The paradox of absolute numbers, standardized incidence rates and proportional share.

16. The outcome of treatment in differentiated thyroid cancer according to recommendations in current Dutch and American guidelines.

17. Impact of Delay on Hospitalization in Older Patients With Head and Neck Cancer: A Multicenter Study.

18. Prediction of Poor Outcome for Cutaneous Squamous Cell Carcinoma of the Head and Neck Comparing Classification Systems: A Competing Risk Analysis.

19. The effect of delayed primary treatment initiation on adverse events and recurrence in older head and neck cancer patients.

20. The effect of treatment delay on quality of life and overall survival in head and neck cancer patients.

21. The Effect of Tumor Characteristics and Location on the Extent of Lymph Node Metastases of Head and Neck Cutaneous Squamous Cell Carcinoma.

22. Association of histological features with laryngeal squamous cell carcinoma recurrences: a population-based study of 1502 patients in the Netherlands.

24. Age-group-specific trend analyses of oropharyngeal squamous cell carcinoma incidence from 1989 to 2018 and risk factors profile by age-group in 2015-2018: a population-based study in The Netherlands.

25. Age-related Differences in Tumour Characteristics and Prognostic Factors for Disease Progression in Cutaneous Squamous Cell Carcinoma of the Head and Neck.

26. Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: A nationwide population-based analysis.

27. A population-based study of the epidemiology of oral squamous cell carcinoma in the Netherlands 1989-2018, with emphasis on young adults.

28. Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm.

29. Determinants of delay and association with outcome in head and neck cancer: A systematic review.

30. Second primary tumours after squamous cell carcinoma of the oral cavity.

31. Determinants of delay in the head and neck oncology care pathway: The next step in value-based health care.

32. Incidental findings during the diagnostic work-up in the head and neck cancer pathway: Effects on treatment delay and survival.

33. To what extent has the last two decades seen significant progress in the management of older patients with head and neck cancer?

34. Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands.

35. Predictors for distant metastasis in head and neck cancer, with emphasis on age.

36. Surgical Complications and Referral Patterns in 567 Patients with Differentiated Thyroid Cancer in the Northern Region of the Netherlands: A Population-Based Study Towards Clinical Management Implementation.

38. Onset of hypothyroidism after total laryngectomy: Effects of thyroid gland surgery and preoperative and postoperative radiotherapy.

39. Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study.

40. Predictors for failure of supraglottic superimposed high-frequency jet ventilation during upper airway surgery in adult patients; a retrospective cohort study of 224 cases.

41. Is C-11 Methionine PET an alternative to 18-F FDG-PET for identifying recurrent laryngeal cancer after radiotherapy?

42. Variation in Integrated Head and Neck Cancer Care: Impact of Patient and Hospital Characteristics.

43. Sinonasal cancer in The Netherlands: Follow-up of a population-based study 1989-2014 and incidence of occupation-related adenocarcinoma.

44. High sensitivity and negative predictive value of sentinel lymph node biopsy in a retrospective early stage oral cavity cancer cohort in the Northern Netherlands.

45. Rare cancers in The Netherlands: a population-based study.

46. What drives centralisation in cancer care?

47. Age-specific incidence and treatment patterns of head and neck cancer in the Netherlands-A cohort study.

48. Viable tumor in salvage neck dissections in head and neck cancer: Relation with initial treatment, change of lymph node size and human papillomavirus.

49. Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands.

50. Feedback preferences of patients, professionals and health insurers in integrated head and neck cancer care.